BIOMARKER:

PIK3CA mutation + HR positive

Entrez ID:

2099; 5290; 5241

Related biomarkers:

‹

›

PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib Sensitive: A1 - Approval	alpelisib Sensitive: A1 - Approval
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline	CDK6 inhibitor + alpelisib Sensitive: A2 - Guideline
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline	CDK4 inhibitor + alpelisib Sensitive: A2 - Guideline
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	Hormone Receptor Positive Breast Cancer Hormone Receptor Positive Breast Cancer	alpelisib Sensitive: C1 - Off-label	alpelisib Sensitive: C1 - Off-label
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	GDC-0077 Sensitive: C2 – Inclusion Criteria	GDC-0077 Sensitive: C2 – Inclusion Criteria
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	palbociclib + GDC-0077 Sensitive: C3 – Early Trials	palbociclib + GDC-0077 Sensitive: C3 – Early Trials
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	alpelisib + GDC-0032 Sensitive: C3 – Early Trials	alpelisib + GDC-0032 Sensitive: C3 – Early Trials
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	trastuzumab Resistant: C3 – Early Trials	trastuzumab Resistant: C3 – Early Trials
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Positive Breast Cancer HER2 Positive Breast Cancer	ado-trastuzumab emtansine Sensitive: C3 – Early Trials	ado-trastuzumab emtansine Sensitive: C3 – Early Trials
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK4 inhibitor Resistant: C3 – Early Trials	CDK4 inhibitor Resistant: C3 – Early Trials
PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	PIK3CA mutation + HR positive PIK3CA mutation + HR positive	HER2 Negative Breast Cancer HER2 Negative Breast Cancer	CDK6 inhibitor Resistant: C3 – Early Trials	CDK6 inhibitor Resistant: C3 – Early Trials